https://mindmedicinelaw.com/briefing/self-medication-with-psychedelics-risks-and-policy-implications-20261001-45959The Psychedelic Journalen2026-10-01T22:04:05.099677+00:00Self-Medication with Psychedelics: Risks and Policy Implicationsself-medication, psychedelics, public health, harm reduction, policy, clinical trials, psychiatric risk, regulation, adverse eventshttps://mindmedicinelaw.com/briefing/ssdp-mobilizes-to-shape-fda-psychedelic-drug-comment-period-20261001-45982The Psychedelic Journalen2026-10-01T22:03:50.612576+00:00SSDP Mobilizes to Shape FDA Psychedelic Drug Comment Periodssdp, fda psychedelic regulations, public comment process, grassroots drug policy, federal policymaking, psychedelic advocacy, regulatory frameworks, youth engagement, community organizations, drug policy reformhttps://mindmedicinelaw.com/briefing/big-data-in-psychiatric-and-psychedelic-research-opportunities-and-cautions-20261001-45756The Psychedelic Journalen2026-10-01T15:07:31.013138+00:00Big Data in Psychiatric and Psychedelic Research: Opportunities and Cautionsbig data, psychiatric research, psychedelic science, clinical trials, genomics, neuroimaging, methodological rigor, data quality, regulatory policy, artificial intelligencehttps://mindmedicinelaw.com/briefing/dea-proposes-stricter-reporting-for-suspicious-psychedelic-orders-20261001-45697The Psychedelic Journalen2026-10-01T15:06:09.908087+00:00DEA Proposes Stricter Reporting for Suspicious Psychedelic Ordersdea, suspicious order reporting, controlled substances, psychedelic research, compliance, clinical trials, supply chain, regulatory risk, schedule i substanceshttps://mindmedicinelaw.com/briefing/dea-proposes-365-day-reexport-window-for-controlled-substances-20261001-45690The Psychedelic Journalen2026-10-01T15:05:54.295992+00:00DEA Proposes 365-Day Reexport Window for Controlled Substancesdea, reexportation period, controlled substances, psychedelic research, international supply chain, regulatory compliance, clinical trials, policy change, pharmaceutical logisticshttps://mindmedicinelaw.com/briefing/neuroscience-based-psychiatry-rethinking-diagnosis-for-psychedelic-therapies-20260930-45745The Psychedelic Journalen2026-10-01T15:06:28.032240+00:00Neuroscience-Based Psychiatry: Rethinking Diagnosis for Psychedelic Therapiespsychiatric diagnosis, neuroscience, clinical brain profiling, psychedelic therapies, brain network dynamics, plasticity, biomarker-driven psychiatry, clinical trials, regulatory sciencehttps://mindmedicinelaw.com/briefing/psilocybin-adverse-effects-in-cyclothymia-clinical-and-policy-lessons-20260930-45650The Psychedelic Journalen2026-09-30T22:07:05.261616+00:00Psilocybin Adverse Effects in Cyclothymia: Clinical and Policy Lessonspsilocybin, cyclothymia, mood disorders, adverse effects, clinical trial screening, psychedelic research, risk management, policy implications, mental healthhttps://mindmedicinelaw.com/briefing/va-launches-psilocybin-study-for-veterans-policy-and-research-implications-in-th-20260930-45662The Psychedelic Journalen2026-09-30T22:06:54.084970+00:00VA Launches Psilocybin Study for Veterans: Policy and Research Implications in the USva psilocybin study, veterans mental health, psychedelic research policy, independent research funding, federal clinical trials, ptsd depression treatment, schedule i regulation, data transparency, us psychedelic sciencehttps://mindmedicinelaw.com/briefing/dea-schedule-i-proposal-for-fda-breakthrough-postpartum-depression-drug-20260930-45660The Psychedelic Journalen2026-09-30T22:05:06.687456+00:00DEA Schedule I Proposal for FDA Breakthrough Postpartum Depression Drugdea schedule i, postpartum depression, breakthrough therapy, fda, psychedelic research, clinical trials, controlled substances act, drug policy, research barriers, mental health innovationhttps://mindmedicinelaw.com/briefing/psychedelic-branding-vs-local-narrative-mad-honey-in-nepal-20260929-45715The Psychedelic Journalen2026-10-01T15:07:49.500877+00:00Psychedelic Branding vs. Local Narrative: Mad Honey in Nepalmad honey, psychedelic discourse, Nepal, local narrative, grayanotoxins, ethnography, cultural legitimacy, psychedelic industry, policy implications, traditional medicinehttps://mindmedicinelaw.com/briefing/evaluating-psychedelic-harm-reduction-new-framework-for-event-settings-20260929-45551The Psychedelic Journalen2026-09-30T22:05:38.818260+00:00Evaluating Psychedelic Harm Reduction: New Framework for Event Settingspsychedelic harm reduction, event health infrastructure, zendo project, peer support, public health policy, mixed-methods evaluation, non-clinical psychedelic use, framework development, safety at festivals, policy implicationshttps://mindmedicinelaw.com/briefing/ketamine-vs-ect-for-severe-depression-meta-analysis-shifts-clinical-debate-20260929-45595The Psychedelic Journalen2026-09-30T22:05:22.277062+00:00Ketamine vs ECT for Severe Depression: Meta-Analysis Shifts Clinical Debateketamine, electroconvulsive therapy, treatment-resistant depression, meta-analysis, neurocognitive outcomes, clinical guidelines, psychiatry, policy, payer decisionshttps://mindmedicinelaw.com/briefing/meta-analysis-psychedelics-anti-inflammatory-effects-and-policy-implications-20260928-45800The Psychedelic Journalen2026-10-01T15:05:31.608526+00:00Meta-Analysis: Psychedelics’ Anti-Inflammatory Effects and Policy Implicationspsychedelics, anti-inflammatory, immunomodulation, serotonergic, clinical trials, policy implications, autoimmune disease, FDA, biomarkers, public healthhttps://mindmedicinelaw.com/briefing/emergency-management-of-emerging-synthetic-drug-intoxications-20260928-45553The Psychedelic Journalen2026-09-30T22:07:16.571963+00:00Emergency Management of Emerging Synthetic Drug Intoxicationsemerging synthetic drugs, emergency medicine, toxidrome recognition, psychiatric complications, synthetic cannabinoids, synthetic cathinones, nitazenes, xylazine, clinical toxicology, integrated carehttps://mindmedicinelaw.com/briefing/systematic-review-anti-inflammatory-effects-of-psychedelics-in-preclinical-model-20260928-45584The Psychedelic Journalen2026-09-30T22:06:25.787984+00:00Systematic Review: Anti-Inflammatory Effects of Psychedelics in Preclinical Modelspsychedelics, anti-inflammatory effects, systematic review, serotonergic psychedelics, preclinical models, human trials, immunomodulation, cytokines, clinical trial design, translational researchhttps://mindmedicinelaw.com/briefing/rapid-acting-and-neuromodulatory-ocd-treatments-psilocybin-and-beyond-20260928-45585The Psychedelic Journalen2026-09-30T22:06:12.692672+00:00Rapid-Acting and Neuromodulatory OCD Treatments: Psilocybin and Beyondpsilocybin, ketamine, treatment-resistant ocd, neuromodulation, rTMS, deep brain stimulation, stress pathways, clinical trials, regulatory status, biomarkershttps://mindmedicinelaw.com/briefing/persistent-perceptual-abnormalities-in-psychedelic-users-new-insights-from-senso-20260928-45552The Psychedelic Journalen2026-09-30T22:05:56.984922+00:00Persistent Perceptual Abnormalities in Psychedelic Users: New Insights from Sensory Processing Researchpersistent perceptual abnormalities, psychedelic research, sensory processing, conditioned hallucinations, clinical trial risk, public health policy, decision precision, visual discrimination, psilocybin, LSDhttps://mindmedicinelaw.com/briefing/cyp2d6-inhibition-and-ibogaine-screening-gaps-in-us-military-health-policy-20260926-45774The Psychedelic Journalen2026-10-01T15:07:07.398780+00:00CYP2D6 Inhibition and Ibogaine: Screening Gaps in US Military Health Policycyp2d6 inhibition, ibogaine therapy, military health system, pharmacogenomics, psychedelic screening, drug-drug interactions, clinical trial design, precision medicine, adverse events, policy developmenthttps://mindmedicinelaw.com/briefing/filament-health-expands-psilocybin-supply-for-italian-trd-trial-20260925-45661The Psychedelic Journalen2026-09-30T22:06:38.374656+00:00Filament Health Expands Psilocybin Supply for Italian TRD Trialfilament health, psilocybin, treatment-resistant depression, italy, clinical trials, gmp supply, tempo trial, european regulation, pharma-academic partnershiphttps://mindmedicinelaw.com/briefing/s-propargyl-l-cysteine-mitigates-ketamine-induced-effects-in-mice-20260922-46068The Psychedelic Journalen2026-10-02T15:05:36.045494+00:00S-propargyl-L-cysteine Mitigates Ketamine-Induced Effects in Mices-propargyl-l-cysteine, ketamine, neuroinflammation, nf-kb, nlrp3 inflammasome, psychedelic safety, preclinical research, adjunctive therapy, pyroptosis, psychiatric therapeuticshttps://mindmedicinelaw.com/briefing/psychedelics-and-suicidality-clinical-risks-and-policy-implications-20260919-46069The Psychedelic Journalen2026-10-02T15:05:20.511221+00:00Psychedelics and Suicidality: Clinical Risks and Policy Implicationspsychedelics, suicidality, clinical trial safety, psychiatric risk, policy implications, harm reduction, screening protocols, serotonergic system, trial ethicshttps://mindmedicinelaw.com/briefing/chrysin-as-a-neuroprotective-adjunct-in-ketamine-therapy-implications-for-clinic-20260919-45071The Psychedelic Journalen2026-10-01T15:08:04.578697+00:00Chrysin as a Neuroprotective Adjunct in Ketamine Therapy: Implications for Clinical Usechrysin, ketamine neurotoxicity, neuroprotection, oxidative stress, neuroinflammation, clinical adjuncts, psychedelic safety, preclinical research, policy implicationshttps://mindmedicinelaw.com/briefing/employment-risks-in-psychedelic-research-policy-and-ethics-in-focus-20260918-44796The Psychedelic Journalen2026-10-01T15:08:21.651449+00:00Employment Risks in Psychedelic Research: Policy and Ethics in Focuspsychedelic research, employment risks, drug testing, clinical trial ethics, informed consent, policy protections, discrimination, institutional review boards, participant safeguardshttps://mindmedicinelaw.com/briefing/psilocybin-restores-social-behavior-in-sapap3-knockout-mice-implications-for-neu-20260917-45218The Psychedelic Journalen2026-10-01T22:04:17.836685+00:00Psilocybin Restores Social Behavior in SAPAP3 Knockout Mice: Implications for Neuropsychiatric Researchpsilocybin, SAPAP3 knockout mice, social behavior, prefrontal-hippocampal circuitry, neuropsychiatric disorders, OCD, ASD, preclinical research, biomarkers, clinical trial designhttps://mindmedicinelaw.com/briefing/framework-for-defining-dmt-assisted-therapy-in-clinical-trials-20260917-44900The Psychedelic Journalen2026-10-01T15:08:36.052823+00:00Framework for Defining DMT-Assisted Therapy in Clinical Trialsdmt-assisted therapy, psychedelic clinical trials, intervention standardization, regulatory pathways, set and setting, integration protocols, methodological rigor, fda approval, efficacy trials